Search clinical trials for: Trastuzumab deruxtecan
Total 1193 results
-
Daiichi Sankyo, Inc.AstraZenecaRecruiting
-
AstraZenecaDaiichi SankyoCompletedBreast CancerDenmark, Finland, Italy, Norway, Spain, Sweden, Poland, United States, Canada, Germany, Japan, Netherlands, Portugal, Switzerland, Australia, United Kingdom, Belgium, Ireland
-
Daiichi Sankyo, Inc.AstraZenecaRecruitingBreast Cancer | Advanced Solid TumorUnited States, Spain, Canada, France
-
Fudan UniversityNot yet recruitingTriple-Negative Breast CancerChina
-
Fudan UniversityActive, not recruiting
-
Cancer Trials IrelandRecruitingHER2-positive Breast CancerIreland
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingGastric or Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
MedSIRDaiichi Sankyo, Inc.Not yet recruitingBreast Cancer | Metastatic Breast Cancer
-
Cancer Institute and Hospital, Chinese Academy...Not yet recruiting
-
National Cancer Institute (NCI)SuspendedOsteosarcoma | Recurrent OsteosarcomaUnited States
-
Medical University of ViennaDaiichi Sankyo, Inc.CompletedBreast Cancer Stage IVAustria
-
National Cancer Institute (NCI)RecruitingAnatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditionsUnited States
-
National Cancer Center Hospital EastDaiichi Sankyo Co., Ltd.RecruitingGastric Adenocarcinoma | Gastroesophageal Junction AdenocarcinomaJapan
-
AstraZenecaRecruitingAdvanced Solid MalignanciesUnited States, Korea, Republic of, Spain, Australia, Sweden, Germany, United Kingdom
-
Daiichi Sankyo, Inc.AstraZeneca; Daiichi Sankyo Co., Ltd.Active, not recruitingNon-Small Cell Lung CancerUnited States, Spain, Japan, Netherlands, France
-
Daiichi Sankyo Co., Ltd.AstraZeneca; Daiichi Sankyo, Inc.CompletedColorectal NeoplasmUnited States, Spain, Japan, Italy, United Kingdom
-
Daiichi SankyoAstraZenecaActive, not recruitingNon-Small Cell Lung CancerUnited States, Spain, Korea, Republic of, Italy, France, Japan, Taiwan, Netherlands, Australia, Canada
-
Daiichi Sankyo, Inc.AstraZeneca; NSABP Foundation Inc; German Breast Group; Spanish Breast Cancer Research...Active, not recruitingHER2-Positive Primary Breast Cancer | Residual Invasive Breast CancerUnited States, Spain, France, Germany, Korea, Republic of, United Kingdom, Denmark, Israel, Belgium, Taiwan, Chile, Italy, Japan, Peru, Portugal, China, Turkey, Canada, Ireland, Australia, Greece, Czechia, Singapore, Poland, Romania, Arge... and more
-
Hospital Israelita Albert EinsteinAstraZenecaRecruiting
-
The Netherlands Cancer InstituteAstraZeneca; Daiichi SankyoNot yet recruiting
-
Spanish Breast Cancer Research GroupAstraZenecaRecruitingMetastatic Breast Cancer | Locally Advanced Breast CancerSpain
-
Yonsei UniversityNot yet recruiting
-
Yonsei UniversityNot yet recruitingNon Small Cell Lung CancerKorea, Republic of
-
Seagen Inc.Active, not recruitingHER2 Positive Breast CancerUnited States
-
Daiichi SankyoRecruitingBreast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast CancerChina
-
Daiichi SankyoAstraZenecaCompletedAdenocarcinoma Gastric Stage IV With Metastases | Adenocarcinoma - GEJUnited States, Spain, Belgium, Italy, United Kingdom
-
Fox Chase Cancer CenterNational Comprehensive Cancer Network; Puma Biotechnology, Inc.RecruitingGastric CancerUnited States
-
Enliven TherapeuticsRecruitingHER2-positive Metastatic Breast Cancer | HER2 Gene Mutation | HER2 Mutant Non-small Cell Lung Cancer | HER2 AmplificationUnited States, Spain, Korea, Republic of, Taiwan, Italy, Australia, France
-
Memorial Sloan Kettering Cancer CenterAstraZenecaRecruitingGlioblastoma | Brain Cancer | Metastatic Cancer | Recurrent Glioblastoma | Leptomeningeal MetastasisUnited States
-
Filipa Lynce, MDAstraZeneca; Daiichi Sankyo, Inc.RecruitingBreast Cancer | HER2-positive Breast Cancer | Invasive Breast Cancer | Inflammatory Breast Cancer Stage III | HER2 Low Breast AdenocarcinomaUnited States
-
M.D. Anderson Cancer CenterDaiichi Sankyo, Inc.Recruiting
-
Daiichi SankyoCompletedHER2-positive Breast CancerSpain, Ireland, Italy
-
AstraZenecaDaiichi Sankyo Co., Ltd.RecruitingAdvanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)China
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingHER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction AdenocarcinomaAustria, Belgium, Germany, Italy
-
AstraZenecaDaiichi SankyoActive, not recruitingHER2-mutant Non-Small Cell Lung CancerChina
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingMetastatic Breast Cancer | Unresectable Breast Cancer | HER2-low Expressing Breast CancerAustria, Belgium, Italy, Spain, France, Switzerland, Denmark, Norway, Sweden
-
MedSIRDaiichi Sankyo, Inc.CompletedAdvanced Breast Cancer | HER2-positive Breast Cancer | Brain Metastases | Leptomeningeal MetastasisSpain, Portugal
-
University of SouthamptonAstraZeneca; Natera, Inc.RecruitingGastrooesophageal CancerUnited Kingdom
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingHER2-positive Breast Cancer | Early-stage Breast Cancer | Adjuvant Treatment After Trastuzumab | RCB Classification 1-2 | NeratiniChina
-
QuantumLeap Healthcare CollaborativeRecruitingSolid Tumor | Metastatic Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Solid Tumor, Adult | Solid Carcinoma | HER2-positive Metastatic Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Estrogen Receptor Positive... and other conditionsUnited States
-
Daiichi SankyoAstraZeneca; Daiichi Sankyo Co., Ltd.Active, not recruitingBreast CancerUnited States, Canada, Spain, Belgium, China, Italy, Korea, Republic of, Taiwan, Australia, Japan, Brazil, France, Germany, United Kingdom, Hong Kong
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingAdvanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,BreastItaly, Spain, United States, France, Korea, Republic of, Japan, Canada, Denmark, Belgium
-
Fudan UniversityNot yet recruiting
-
Samsung Bioepis Co., Ltd.CompletedHER2 Positive Early or Locally Advanced Breast CancerCzechia
-
AstraZenecaDaiichi SankyoRecruitingLocally Advanced or Metastatic Non-Small Cell Lung CancerChina, Korea, Republic of, United States, Germany, Italy, Poland, Belgium, Mexico, Turkey, Spain, France, Canada, Taiwan, Brazil, Austria, Hong Kong, India, Japan, Netherlands, Denmark
-
Daiichi SankyoMerck Sharp & Dohme LLC; AstraZeneca UK LimitedRecruitingBreast Cancer | Non-small Cell Lung CarcinomaUnited States, Spain, United Kingdom, France
-
West German Study GroupAstraZenecaNot yet recruitingHER2-positive Early Breast CancerGermany
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingAdvanced Breast Cancer | Metastatic Breast CancerChina
-
AstraZenecaDaiichi SankyoRecruitingLocally Advanced or Metastatic Non-Small Cell Lung CancerKorea, Republic of, Italy, Poland, Malaysia, Taiwan, Thailand, United States, France, Netherlands, Philippines, Canada, Singapore, Spain, Turkey, Australia, Belgium, Israel